{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:43:15Z","timestamp":1790239395110,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.ejca.2015.08.002","type":"journal-article","created":{"date-parts":[[2015,8,25]],"date-time":"2015-08-25T23:28:23Z","timestamp":1440545303000},"page":"2615-2623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials"],"prefix":"10.1016","volume":"51","clinical-trial-number":[{"clinical-trial-number":"nct00753688","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"F.","family":"Duffaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sleijfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Liti\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Le Cesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Papai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Judson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sch\u00f6ffski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.P.","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dewji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Marreaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Verweij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.T.","family":"van der Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2015.08.002_b0005","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/annonc\/mdh309","article-title":"Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma","volume":"15","author":"Yoon","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2015.08.002_b0010","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jss.2006.01.023","article-title":"Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression","volume":"135","author":"Yoon","year":"2006","journal-title":"J Surg Res"},{"key":"10.1016\/j.ejca.2015.08.002_b0015","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s10434-001-0260-9","article-title":"Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade","volume":"8","author":"Chao","year":"2001","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2015.08.002_b0020","first-page":"3591","article-title":"Expression of vascular endothelial growth factor and its receptor, KDR\/Flk-1, in soft tissue sarcomas","volume":"25","author":"Pakos","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2015.08.002_b0025","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1054\/bjoc.2001.1837","article-title":"Concentration of vascular endothelial growth factor in the tumor tissue as a prognostic factor of soft tissue sarcomas","volume":"84","author":"Yudoh","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2015.08.002_b0030","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1634\/theoncologist.2008-0188","article-title":"Angiogenesis inhibition in non-GIST soft tissue sarcomas","volume":"13","author":"Sleijfer","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2015.08.002_b0035","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2015.08.002_b0040","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","article-title":"Adverse effects of anti-cancer agents that target the VEGF pathway","volume":"6","author":"Chen","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2015.08.002_b0045","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2015.08.002_b0050","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","article-title":"Sunitinib in patients with metastatic renal cell carcinoma","volume":"295","author":"Motzer","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2015.08.002_b0055","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1158\/1078-0432.CCR-06-1249","article-title":"Sorafenib for the treatment of advanced renal cell carcinoma","volume":"12","author":"Kane","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2015.08.002_b0060","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","volume":"27","author":"Sleijfer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.08.002_b0065","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00228-010-0815-4","article-title":"Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis of randomized controlled trials","volume":"66","author":"An","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ejca.2015.08.002_b0070","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with renal cell carcinoma","volume":"103","author":"Rini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2015.08.002_b0075","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/annonc\/mdm184","article-title":"Hypertension as a predictive factor of sunitinib activity","volume":"18","author":"Rixe","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2015.08.002_b0080","unstructured":"Nozawa M, Nagae S, Nishigaki K, et al. Association of hypertension with objective response in patients treated with sorafenib (Abstract 341). Presented at the American Society of Clinical Oncology genitourinary cancers symposium, Orlando, FL, Feb 28, 2009."},{"issue":"Suppl.","key":"10.1016\/j.ejca.2015.08.002_b0085","article-title":"Association of hypertension with overall outcome in patients taking sorafenib in advanced hepatocellular carcinoma","volume":"8","author":"Kim","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.08.002_b0090","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1093\/annonc\/mds179","article-title":"Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib","volume":"23","author":"George","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2015.08.002_b0095","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1471-2407-12-107","article-title":"The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure \u2013 one institution study","volume":"12","author":"Rutkowski","year":"2012","journal-title":"BMC Cancer"},{"issue":"Suppl.","key":"10.1016\/j.ejca.2015.08.002_b0100","article-title":"Association of diastolic blood pressure (dBP)\u2a7e90mmHg with overall survival (OS) in patients treated with axitinib (AG-013736)","volume":"26","author":"Rini","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.08.002_b0105","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1634\/theoncologist.2013-0107","article-title":"Efficacy and safety of bevacuzimab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials","volume":"18","author":"Hurwitz","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2015.08.002_b0110","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/jnci\/djr328","article-title":"Re: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Van den Meiracker","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2015.08.002_b0115","series-title":"Common terminology criteria for adverse events version 3.0 (CTCAE)","author":"Cancer Therapy Evaluation Program","year":"2003"},{"key":"10.1016\/j.ejca.2015.08.002_b0120","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1200\/JCO.2009.22.2273","article-title":"Effective strategies of hypertension after vascular endothelial growth factor signaling inhibition therapy: results form a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors","volume":"27","author":"Langenberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.08.002_b0125","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1200\/JCO.2008.16.1612","article-title":"Association of vascular endothelial growth factor and vascular endothelial receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100","volume":"26","author":"Schneider","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.08.002_b0130","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report on the Joint National Committee on Prevention, detection, Evaluation, and Treatment of High Blood pressure","volume":"42","author":"Chabonian","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.ejca.2015.08.002_b0135","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1634\/theoncologist.2011-0163","article-title":"Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs","volume":"16","author":"Dienstmann","year":"2011","journal-title":"Oncologist"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915007777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915007777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T01:00:53Z","timestamp":1537405253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804915007777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":27,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0959804915007777"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2015.08.002","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2015.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}